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Abstract
Background: Bisphenol A is widely used in food and drinks packaging. There is evidence of associations between raised
urinary bisphenol A (uBPA) and increased incidence of reported cardiovascular diagnoses.
Methodology/Principal Findings: To estimate associations between BPA exposure and angiographically graded coronary
atherosclerosis. 591 patients participating in The Metabonomics and Genomics in Coronary Artery Disease (MaGiCAD) study
in Cambridgeshire UK, comparing urinary BPA (uBPA) with grades of severity of coronary artery disease (CAD) on
angiography. Linear models were adjusted for BMI, occupational social class and diabetes status. Severe (one to three
vessel) CAD was present in 385 patients, 86 had intermediate disease (n = 86) and 120 had normal coronary arteries. The
(unadjusted) median uBPA concentration was 1.28 ng/mL with normal coronary arteries, and 1.53 ng/mL with severe CAD.
Compared to those with normal coronary arteries, uBPA concentration was significantly higher in those with severe CAD
(OR per uBPA SD=5.96 ng/ml OR= 1.43, CI 1.03 to 1.98, p = 0.033), and near significant for intermediate disease (OR= 1.69,
CI 0.98 to 2.94, p = 0.061). There was no significant uBPA difference between patients with severe CAD (needing surgery)
and the remaining groups combined.
Conclusions/Significance: BPA exposure was higher in those with severe coronary artery stenoses compared to those with
no vessel disease. Larger studies are needed to estimate true dose response relationships. The mechanisms underlying the
association remain to be established.
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Introduction
Bisphenol A (BPA) is a synthetic monomer used in the
manufacture of polycarbonate plastics and in the epoxy resins
lining food and beverage containers, and is one of the world’s
highest production volume chemicals [1]. BPA is classified as an
endocrine disrupting chemical (EDC) due to reported interference
in hormonal function and signaling, especially in relation to
estrogen receptor-mediated pathways [2]. Ubiquitous human
exposure to BPA is evident from the presence of detectable
concentrations of BPA metabolites in the urine of 80–90% of the
population worldwide [3,4]. The main source of exposure for
humans is not clearly understood, but is most likely through
consumption of packaged food and beverages, with additional
exposure from drinking water, dental sealants, dermal exposure
and inhalation of household dusts [5].
The first major epidemiological analyses of adult health effects
associated with exposure to BPA involved a study of 1455 adults
aged 18 to 74 years with measured urinary BPA (uBPA) from the
US National Health and Nutrition Survey (NHANES) 2003–2004
[6]. Higher BPA concentrations were associated with cardiovas-
cular diagnoses (OR per one SD increase in BPA concentration
1.39, 95% CI 1.18–1.63; p = 0.001 with full adjustment). The
association with cardiovascular disease was also present in a
separate population representative sample in NHANES 2005/06
(n= 1493), despite a decrease in uBPA concentrations of around
30% compared to the 2003/04 results. Associations with diabetes
and some liver enzyme changes did not reach significance in the
2005–2006 data, but remained significant in pooled data [7]. This
cross-sectional data has recently been augmented by a longitudinal
study, in which higher uBPA concentrations were shown to predict
first diagnoses of coronary artery disease (CAD) during a 6 year
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follow-up in the European Prospective Investigation of Cancer
EPIC-Norfolk study, greatly strengthening the evidence for a
causal role for BPA in the disease process [8]. In this prospective
association the uBPA concentrations were relatively low, with
median values of 1.35 ng/mL in the EPIC-Norfolk cases and
1.24 ng/mL in the controls, compared to a median value of
2.6 ng/ml (interquartile range 1.3 to 5.6) in the original NHANES
study of 2003/4 [8,9].
The mechanism by which exposure to BPA affects CAD
incidence is unknown. Our sensitivity analyses showed that the
association between uBPA and incident CAD appears to be
independent of classical CAD risk factors [8]. In particular,
exclusion of those with obesity and adjustment for blood lipid
concentrations and levels of physical activity had little effect,
suggesting that obesity related risks and incidental higher BPA
ingestion (and hence excretion) are an unlikely explanation for the
findings.
Previous studies have involved self-reported diagnoses, whilst
incident disease was identified from recorded hospital admission or
death certification. In the current study, we tested the hypothesis
that greater exposure to BPA would be associated with coronary
atherosclerosis, to gain a clearer understanding of the nature and
specificity of the association between BPA exposure and CAD. We
studied a population with vessel disease precisely defined at
angiography, from The Metabonomics and Genomics in Coro-
nary Artery Disease (MaGiCAD) study, an angiography referral
study from East Anglia, UK. This patient population is drawn
from the EPIC-Norfolk and neighbouring geographical areas,
referred to the regional angiography centre at Papworth Hospital.
Methods
The MaGiCAD study was designed to study risk factors for
coronary heart disease in the UK, and was carried out at
Papworth Hospital NHS Trust, Cambridgeshire UK, a regional
cardiac centre [10]. All patients attending for a diagnostic
angiogram were eligible, excluding those who had previously
had a heart transplant or were unable to give informed consent:
1336 patients agreed to participate. For logistic reasons, patients
undergoing procedures between 10:00 and 14:30 were included (to
allow processing of blood, urine specimens etc). In a comparison of
those patients recruited against those not recruited, there were no
significant differences in disease severity (assessed using angio-
gram). All of the patients attending Papworth Hospital for an
angiogram must have a suspected cardiac disorder because of the
risk associated with the diagnostic procedure. Nevertheless, 19.2%
(n= 235 of 1,221 with angiography results) of these patients had
normal coronary arteries. The sub-group of patients with
angiographically normal coronary arteries, despite their apparent
lack of coronary atherosclerosis, may have another cardiac
disorder or suspected cardiac disorder (e.g. a diseased aortic valve
or non-attributable chest pain).
For the current analysis, we included the 591 patients who
provided a useable urine specimen during their angiography visit
and who were undergoing first angiographies: urine samples were
collected between 28 November 2001 and 9 November 2004 and
stored at 280uC.
Classification of Vessel Disease
The index used to classify coronary disease severity was a minor
modification of that described by Ringqvist [11], with scores
ranging from normal coronary arteries to disease in three vessels.
The right coronary artery, left anterior descending artery, and left
circumflex artery were considered diseased if there was a $70%
reduction in the internal diameter of the vessel or major subvessels
(Table 1). The left main stem coronary artery was considered
diseased if there was a $50% reduction in diameter. The number
of vessels diseased was calculated according to right or left
dominance of the coronary circulation, as summarised in Table 1.
Participants who had evidence of disease but did not reach the
criteria outlined above were classified as having disease of
intermediate severity for the purpose of this study. Participants
with no evidence of disease were classified as having normal
coronary arteries.
To avoid possible bias of interpretation by the original clinician,
the angiogram of every patient in the study was re-read. The video
file was extracted from the hospital database and the anonymised
angiogram was read by two clinicians and a native vessel disease
status calculated. Between each of the independent reads and the
result of the angiogram read for clinical purposes there was
approximately 70% identity (disease status the same), and 95%
similarity (disease statuses within one category of each other).
Analysis of Urinary BPA Concentrations
Analysis of uBPA metabolites in the spot urine specimens was
performed in 2010/11 by Brixham Environmental Laboratory,
Division of Analytical Chemistry (a division of AstraZeneca PLC)
in compliance with Good Laboratory Practice, EU Directive 88/
32/EEC. Because orally administered BPA is considered to be
rapidly and completely excreted, and is stable in frozen urine,
urine is the body fluid most appropriate for biomonitoring
assessment of BPA exposure and we followed WHO guidelines
over study design to evaluate exposure [12]. A comprehensive,
GLP compliant quality control procedure was followed including
reagent blanks and measurement of both free and conjugated
BPA, to confirm that there was minimal leaching of BPA from
vessel walls. Total (free and conjugated) urinary concentrations of
BPA were obtained using online, solid-phase extraction (SPE)
coupled with high performance liquid chromatography (LC)-
isotope dilution tandem mass spectrometry (MS/MS) with peak
focusing [13], based on the methods employed by NHANES and
adopted by the Division of Environmental Health Laboratory
Sciences, National Centre for Environmental Health, Centre for
Disease Prevention,(CDC) [3]. Calibration was linear from 0.50–
100 mg/L (R2.0.996), limit of detection was ,0.50 ng/ml uBPA,
limit of quantification, 0.50 ng/ml uBPA, lowest calibration
standard gave a signal height:noise ratio .10 (relative standard
deviations ,20%, all other standards ,15%).
Statistical Analysis
As previously [13] our lower level of accurate BPA detection
(LLOD) was ,0.5 ng/ml, below which values of 0.28 were
assigned, following the methods of Calafat and colleagues [3] (117
cases reassigned). Logistic regression models were used to estimate
odds ratios for CAD status as outcome with uBPA concentrations
(standardized z-scores) and covariates as explanators. Adjustment
was for: age, sex, occupational social class (grouped into uncoded,
professional, managerial, skilled non-manual, skilled manual,
semiskilled, non-skilled) and body mass index (BMI, measured
weight in kilograms divided by the square of measured height in
meters, categorized into: underweight (BMI,18.5), recommended
(BMI 18.5 to 24.9), overweight (BMI 25.0 to 29.9), obese I (BMI
30.0 to 34.9), obese II (BMI 35.0 or above). Sensitivity analyses
included adjustment for smoking (pack years) and alcohol intake
(estimated units per week). Regression models were adjusted for an
available occupationally based social class measure, as Calafat and
colleagues [9] reported that socio-economic status is associated
with BPA concentrations.
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A measure of urine concentration was not available, so we have
provided a sensitivity analysis adjusted for blood urea creatinine
ratio, a validated clinical measure of hydration [14].
Results
There were 591 patients with first angiograms and uBPA values:
one or more severe stenoses were present in 385 (65.1%) patients,
and 120 patients had normal coronary arteries (20.3%). The
remainder of patients had one or more abnormalities in their
coronary arteries, but did not classify as 1-, 2- or 3-VD when
applying the categorisation method used; these 86 patients (14.6%)
were classified as having intermediate disease. Overall, 32% of the
sample was female, but this percentage was 50% and 51.7% in the
intermediate disease and normal coronary artery groups respec-
tively. Those with no stenoses tended to be in the younger age
groups. There was no difference in BMI categories between the
groups or in occupational social class, but those with intermediate
stenoses were less likely to have diabetes.
Bisphenol A concentrations varied from below levels of
detection (n= 117, 16.9%) to 69.4 ng/mL. As in previous
biomonitoring studies, the distribution was strongly skewed with
most values being relatively low (Table 2). The (unadjusted)
median uBPA value was 1.28 ng/mL in those patients with
normal coronary arteries, and 1.53 ng/mL in those with severe
disease. Median uBPA concentration in the relatively small
intermediate group (n= 86, median 1.58 ng/ml) was higher than
in those with severe disease. Overall 17.5% of patients with normal
coronary arteries had uBPA concentrations $3 ng/mL compared
to 30.2% in the intermediate group and 26.7% in the severe
group.
The formal classification of angiography results for clinical
purposes was at the time of assessment primarily into patients with
one or more severe stenoses versus the rest: uBPA was not
associated with severe disease in this dichotomy in age and sex
adjusted models (per uBPA standard deviation = 5.96 nm/ml,
OR=1.14 CI 0.94 to 1.38, p = 0.172) or fully adjusted models
(OR=1.11 CI 0.93 to 1.33, p = 0.24).
On separating those with normal coronary arteries from those
with intermediate severities of disease, in models adjusted for age
and sex only (Table 3), uBPA concentrations were significantly
higher in those with severe CAD (versus no CAD: per uBPA
standard deviation odds ratio was 1.51 95% CI 1.07 to 2.14,
p = 0.019). Comparison of the smaller, intermediate CAD
category to those with normal coronary arteries narrowly missed
significance (OR=1.79 CI 0.98 to 3.27, p = 0.058).
In models comparing patients with severe CAD with patients
with normal coronary arteries additionally adjusted for occupa-
tional social position, BMI category and diabetes status (Table 3),
the estimate was only a little changed: the OR per SD of uBPA
comparing patients with severe disease and no disease was 1.43 (CI
1.03 to 1.98, p = 0.033). Although numbers are small, we also
present comparisons between uBPA in patients with one, two and
three vessel disease versus those with no disease. There were
significant differences between patients with one vessel disease
versus none (OR=1.69 CI 1.02 to 1.98, p= 0.036), but the
comparison between patients with two vessel disease and those
with normal coronary arteries was not significant. The largest
association found was comparing patients with three vessel disease
versus patients with no disease (OR=2.09 CI 1.62 to 3.46,
p = 0.004).
Sensitivity Analyses
We conducted post-hoc sensitivity analyses to check the
robustness of the association of higher uBPA comparing severe
to no vessel disease. Firstly we adjusted the ‘full’ model comparing
severe CAD to the normal artery group additionally for serum
creatinine (to account for renal functioning) and alcohol intake (in
weekly standard units of alcohol per week): the result was little
changed (OR 1.42 CI 1.01 to 1.99, p = 0.043). Secondly we
excluded those aged 75 and over, to avoid possible multiple
morbidity: this had little effect (OR=1.44 CI 1.02 to 2.03,
p = 0.038). Formal tests for interaction between uBPA and age
(p = 0.241) or diabetes status (p = 0.508) were non-significant.
As urine BPA concentrations might be affected by the patient’s
state of hydration we additionally adjusted estimates for the ratio
of blood urea nitrogen and blood creatinine concentrations: the
results of the fully adjusted models as in Table 3 were only
marginally different: intermediate vs none OR=1.70 (CI 0.98 to
2.94, p = 0.060) and severe vessel disease OR=1.51 (CI 1.07 to
2.14, p = 0.020).
Discussion
In this study, we aimed to assess whether increased uBPA was
associated with angiography defined coronary artery stenoses
Table 1. Summary of disease scoring method for reading the MaGICAD study angiograms.
Right Dominant Coronary Circulation Left Dominant Coronary Circulation
*Diseased vessel Score *Diseased vessel Score
Proximal, mid or distal right coronary artery 1 VD Left main coronary artery 3 VD
If no left main coronary artery disease:
Left main coronary artery 2 VD Proximal, mid or distal left anterior descending or 1st or
2nd diagonal artery
1 VD
If no left main coronary artery disease: Proximal, mid or distal left circumflex artery 2 VD
Proximal, mid or distal left anterior descending or 1st or 2nd
diagonal artery
1 VD If no proximal, mid or distal left circumflex
artery disease:
Proximal, mid or distal left circumflex or one obtuse marginal
artery
1 VD Any one of three obtuse marginal 1 VD
Left atrio-ventricular artery, 1st –3rd posterolateral or left
posterior descending artery
1 VD
*Note that vessels are considered diseased according to criteria outlined in the text.
doi:10.1371/journal.pone.0043378.t001
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(coronary atherosclerosis). We studied a relatively small sample
from those undergoing first angiography in a regional cardiac
centre from 2001 to 2004. The centre in question serves the EPIC
Norfolk cohort study population in which we have previously
shown that higher uBPA concentration was predictive of incident
cardiovascular disease [8]. In EPIC-Norfolk, diagnoses were
clinically confirmed from hospital episode data and mortality
records. In the current study, we found evidence of higher uBPA
concentrations in those with intermediate or severe stenoses
compared to those graded as having no coronary artery disease, in
independently read angiograms.
These results are important as they suggest that associations
between uBPA and CAD may be specific to coronary artery
stenosis. Associations between uBPA and cardiovascular disease
have now been reported in three previous studies, in which disease
diagnosis data was drawn from questionnaire self-report [6] or
identified from clinical notes [8]. In NHANES 2003/2004 and
again in NHANES 2005/2006, higher uBPA concentrations were
associated with heart disease (pooled p value ,0.001). A major
limitation of these studies is their cross-sectional nature, leaving
open the possibility of reverse-causation, e.g. that patients with
CAD may have changed their behaviour or diet in a way that
incidentally led to increased exposure to BPA. A prospective
design was therefore adopted with 758 incident CAD cases and
861 controls from the European Prospective Investigation of
Cancer (EPIC-Norfolk), UK study, which concluded that higher
uBPA concentrations (.4 ng/mL) were associated with incident
CAD (OR 1.39 95% CI 1.06 to 1.84, p = 0.020). This longitudinal
study effectively ruled out reverse causation, strengthening the
evidence for causal inference.
A cross-sectional analysis of pooled data from NHANES 2003–
2006 showed that uBPA was associated with general and central
obesity [15], confirming earlier findings of an association between
daily excreted BPA and waist circumference in Italian men [13].
However, sensitivity analyses of the 2011 EPIC study excluded
those with obesity and adjusted for blood lipid concentrations and
Table 2. Characteristics of the sample by severity of coronary artery stenoses.
None Intermediate three vessel Total n % p-value
N % n % n % n %
Total 120 (100) 86 (100) 385 (100) 591 (100)
Gender ,0.001
Female 62 (51.7) 43 (50) 84 (21.8) 189 (32)
Male 58 (48.3) 43 (50) 301 (78.2) 402 (68)
Age-group (years) 0.002
30 to 45 12 (10) 6 (7) 19 (4.9) 37 (6.3)
46 to 64 74 (61.7) 37 (43) 170 (44.2) 281 (47.6)
64 to 84 33 (27.5) 42 (48.8) 189 (49.1) 264 (44.7)
85 to 95 1 (0.8) 1 (1.2) 7 (1.8) 9 (1.5)
BMI category 0.93
#18.5 1 (0.8) 0 (0) 1 (0.3) 2 (0.3)
18.5 to 25 32 (26.7) 24 (27.9) 112 (29.1) 168 (28.4)
.25 to 30 52 (43.3) 37 (43) 178 (46.2) 267 (45.2)
.30 31 (25.8) 23 (26.7) 85 (22.1) 139 (23.5)
Unknown 4 (3.3) 2 (2.3) 9 (2.3) 15 (2.5)
Diabetes
No 111 (92.5) 74 (86.1) 309 (80.3) 494 (83.6) 0.004
Present 5 (4.2) 11 (12.8) 69 (17.9) 85 (14.4)
Unknown 4 (3.3) 1 (1.2) 7 (1.8) 12 (2)
Occupational social class 8 9 20 37 0.111
Unknown 8 (6.7) 9 (10.5) 20 (5.2) 37 (6.3)
Professional 4 (3.3) 2 (2.3) 21 (5.5) 27 (4.6)
Managerial 29 (24.2) 20 (23.3) 102 (26.5) 151 (25.6)
Skilled non-manual 26 (21.7) 20 (23.3) 103 (26.8) 149 (25.2)
Semiskilled non-manual 37 (30.8) 14 (16.3) 70 (18.2) 121 (20.5)
Skilled manual 12 (10) 16 (18.6) 51 (13.3) 79 (13.4)
Non-skilled manual 4 (3.3) 5 (5.8) 18 (4.7) 27 (4.6)
Urinary Bisphenol A concentration (ng/mL)
Mean (Standard deviation) 2.13 (2.73) 3.31 (7.37) 3.82 (6.31) 3.14 (5.96)
Median 1.28 1.77 1.53 1.53
Inter-quartile range 0.69 to 2.26 0.92 to 3.73 0.78 to 3.26 0.78 to 3.03
doi:10.1371/journal.pone.0043378.t002
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levels of physical activity, yet found little effect on the association;
neither did adjustment for vitamin C as a marker of diets poor in
fruit and vegetables, or adjustment for education, smoking or
blood pressure. The uBPA association with CAD incidence in the
EPIC sample therefore appears to have been independent of
conventional CAD risk factors. This conclusion was also reached
in a study of 1016 elderly subjects [16] which showed a weak
relationship between circulating BPA and the thickness and
composition of the intima-media complex in the carotid artery,
considered to be a marker of lipid infiltration of the vascular wall
[17]. The effect remained significant after adjustment for
conventional CAD risk factors, suggesting that any vascular effect
was occurring independently of these.
Our analysis shows that BPA was similarly elevated in patients
with intermediate vessel changes and patients with severe stenoses
(combining the individually small groups with 1-, 2- and 3- vessel
disease). This is consistent with observations that coronary plaques
develop focally, independently, and exhibit morphologic and
histological heterogeneity between and within coronary arteries
[18–20]. Localization of coronary lesions occurs despite similar
exposure to pro-atherosclerotic risk factors and this has been
attributed to localized hemodynamic disturbances, especially to
endothelial shear stress [18,21]. Endothelial shear stress promotes
an athero-protective endothelial cell phenotype, but low endothe-
lial shear stress induces an atherogenic phenotype that reduces
nitric oxide bioavailability, promotes low density lipoprotein
cholesterol uptake and oxidation, recruits inflammatory cells and
promotes smooth muscle cell migration to the intima [18,19].
Localized areas of low endothelial shear stress are found at branch
points, bifurcations and areas of large curvature in coronary
arteries. These regional differences in hemodynamics appear to
prime endothelial cells to respond distinctly to systemic risk factors
[22]. If BPA plays a direct role in promoting atherosclerosis, our
observations of individual differences in plaque burden in the
presence of similar BPA exposure probably reflects the heterogenic
susceptibility of specific vessels, and specific regions within vessels,
to atherogenesis and plaque progression.
The mechanism by which BPA ingestion and metabolism
influences vascular function and risk of cardiovascular disease has
not been elaborated. A number of environmental contaminants
have been associated with vascular endothelial dysfunction [23,24]
and accelerated progression of atherosclerosis [25,26]. We recently
suggested plausible mechanisms by which BPA might increase the
risk of cardiovascular disease [7], including reduced nitric oxide
bioavailability, altered vascular reactivity to endothelin-1, oxida-
tive stress and inflammation. Laboratory exposure studies have
shown that BPA can induce oxidative cellular damage in a range
of experimental contexts [27–29]. For example, oral intake of BPA
over a 30 day period led to oxidative stress in rat hepatocytes.
Circulation of BPA and redistribution around the body could
contribute to oxidative endothelial cell damage, a suggestion
supported by a reported positive associations between urinary BPA
and oxidative stress markers (malondialdehyde and 8-deoxygua-
nosine) in a study of 960 adults [30]. BPA shows estrogen and anti-
androgen activity [31] hence BPA may exert estrogenic effects or
antagonize endogenous estrogens in cardiovascular tissues by
binding to soluble or membrane bound estrogen receptors [32].
We recently reported associations between higher uBPA concen-
trations and higher estrogen receptor beta, (ERb) expression and
estrogen-related receptor alpha (ERRa) expression [33], reinforc-
ing the evidence for estrogenic activity in vivo.
BPA is also capable of causing non-genomic effects in vitro. A
rapid disruption of Ca2+ homeostasis has been shown in a range of
cell types [34] suggesting the involvement of cellular transport
mechanisms and ion channels. Estrogen and estrogen-receptor
modulators can increase the activity of large conductance Ca 2+/
voltage-sensitive K+ (Maxi-K; KCa 1.1) channels [35]. Recently,
BPA in the micromolar range was shown to activate Maxi-K
(KCa1.1) ion channels in human coronary smooth muscle cells in
culture, sufficient to hyperpolarise the membrane potential [36].
The effects of BPA on channel activity were rapid (,1 min) and
Table 3. Odds ratios per SD increase in uBPA (5.96 ng/ml) of diagnosed coronary artery features comparing age and sex adjusted




per SD increase 95%CI p-value
Age and sex adjusted
None 120 1
Intermediate 86 1.79 (0.98 to 3.27) 0.058
Severe 385 1.51 (1.07 to 2.14) 0.019
Fully adjusted models
None 120 1
Intermediate 86 1.69 (0.98 to 2.94) 0.061
Severe 385 1.43 (1.03 to 1.98) 0.033
Fully adjusted detailed models
None 120 1
Intermediate 86 1.69 (0.98 to 2.94) 0.061
1 VD 148 1.42 (1.02 to 1.98) 0.036
2 VD 123 1.20 (0.70 to 2.04) 0.501
3 VD 114 2.09 (1.62 to 3.46) 0.004
Note: full adjustment included age, sex, BMI category, occupational social class and diabetes status.
doi:10.1371/journal.pone.0043378.t003
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reversible and could theoretically lead to a decrease in excitability
in cells that express other voltage dependent ion channels.
Limitations
One limitation of this study is that the BPA measures are from
single spot urine samples, which could be considered as limited
measures of long term exposure. Urine is however the recom-
mended matrix of choice for biomonitoring studies of BPA, since
BPA is rapidly metabolized and excreted from the body and
remains stable in frozen urine on long term storage [3]. Single spot
samples have been found to be moderately sensitive in predicting
an individual’s longer term tertiary BPA categorization [37,38]
measured stability of BPA over 2 week intervals in first voided
urine samples from 60 women and found a Spearman correlation
of 0.5, indicating that around 75% of the variability of BPA was
unaccounted for. Exposure of the general population to BPA is
considered to be primarily from food and beverage consumption
and a recent study has highlighted the inhibitory effect of food on
first pass metabolism, which would lead to a longer residence time
for BPA in the body [39]. There is in addition considerable
evidence for non-food exposure to BPA. For example, Zalko and
colleagues [40] show that viable skin efficiently absorbs and
metabolises BPA, which would bypass first pass metabolism. Given
that BPA is widely found in receipt papers, from where transfer to
skin can occur [41], frequent exposure of the general population to
BPA through this non-food source is a potential additional route of
exposure.
This could help to explain why despite its rapid metabolism,
BPA is present in such a large percentage of the population at any
one time. It is likely that the use of single spot samples would, if
anything, result in a smaller (diluted) estimate of the strength of
association between BPA and CAD.
Another major limitation is our relatively small sample sizes.
Small sample size (n = 86 for the intermediate group) may explain
why the central estimate for the uBPA intermediate vs none vessel
disease estimate is larger than that for the severe vessel disease
group: the very wide confidence intervals on this intermediate
estimate (CI 0.98 to 3.27, Table 3) makes interpretation of this
hazardous and argues for a better powered study. Because of the
temporal variability in BPA exposure and errors in estimation by
urine specimens, larger sample sizes are needed. Although our
strongest association was found on comparing three vessel disease
to none, the intermediate uBPA associations across increasing
severity groups show no obvious dose-response relationship. This
may be due to possible mechanisms of effect, but may well also be
influenced by the very small sample sizes in each specific severity
group. Larger studies are clearly needed to estimate the dose
response curve for the detailed groupings. It is noteworthy that
Ning et al [42] did not find a monotonic association between BPA
and the risk of the presence of self-reported diabetes, despite clear
statistical differences across quartiles of exposure.
Much remains unknown about the mechanisms involved in the
association between BPA and CAD in humans. Future scientific
work in humans is, of course, constrained by ethical limits and the
practicality of repeated BPA exposure measures and long term
follow-up studies. Without these constraints, controlled trials
would be needed to prove causation in humans, but such evidence
is almost certainly beyond reach.
Conclusions
In our relatively small sample of patients investigated for
ischemic heart disease referred for coronary angiography, BPA
exposure (evident in urinary BPA concentrations) was higher in
those with severe coronary artery stenoses compared to those with
no vessel disease. Larger studies are needed to estimate true dose
response relationships. The mechanisms underlying the associa-
tion remain to be established.
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